Previous Close | 0.3500 |
Open | 0.4000 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 7.50 |
Expire Date | 2024-05-17 |
Day's Range | 0.3500 - 0.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 21 |
HAYWARD, Calif., May 20, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock
HAYWARD, Calif., May 16, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
HAYWARD, Calif., May 14, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ("Pulse"), today announced enhancements to its executive leadership team to support its next pivotal phase of growth.